PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
22.23%
Positive EBIT growth while AXSM is negative. John Neff might see a substantial edge in operational management.
22.23%
Positive operating income growth while AXSM is negative. John Neff might view this as a competitive edge in operations.
18.34%
Positive net income growth while AXSM is negative. John Neff might see a big relative performance advantage.
32.95%
Positive EPS growth while AXSM is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
32.95%
Positive diluted EPS growth while AXSM is negative. John Neff might view this as a strong relative advantage in controlling dilution.
21.91%
Share count expansion well above AXSM's 2.52%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
21.91%
Diluted share count expanding well above AXSM's 2.52%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
46.02%
OCF growth above 1.5x AXSM's 2.42%. David Dodd would confirm a clear edge in underlying cash generation.
46.06%
FCF growth above 1.5x AXSM's 2.48%. David Dodd would verify if the firm’s strategic investments yield superior returns.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-8783.56%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
85.25%
Positive OCF/share growth while AXSM is negative. John Neff might see a comparative advantage in operational cash viability.
76.39%
Positive 3Y OCF/share CAGR while AXSM is negative. John Neff might see a big short-term edge in operational efficiency.
-13944.86%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
85.03%
Positive 5Y CAGR while AXSM is negative. John Neff might view this as a strong mid-term relative advantage.
64.22%
Positive short-term CAGR while AXSM is negative. John Neff would see a clear advantage in near-term profit trajectory.
5293.49%
Positive growth while AXSM is negative. John Neff might see a strong advantage in steadily compounding net worth over a decade.
188.65%
Positive 5Y equity/share CAGR while AXSM is negative. John Neff might see a clear edge in retaining earnings or managing capital better.
367.41%
Positive short-term equity growth while AXSM is negative. John Neff sees a strong advantage in near-term net worth buildup.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-15.58%
Negative asset growth while AXSM invests at 9.01%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-38.36%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
No Data
No Data available this quarter, please select a different quarter.
-22.17%
Our R&D shrinks while AXSM invests at 0.51%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-22.47%
We cut SG&A while AXSM invests at 6.79%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.